Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence

https://doi.org/10.4081/ejh.2020.3098

Authors

  • Stanislav Ziaran Department of Urology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. https://orcid.org/0000-0002-5487-0875
  • Stefan Harsanyi Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava , Slovakia. https://orcid.org/0000-0002-7889-4898
  • Katarina Bevizova Institute of Anatomy, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  • Zuzana Varchulova Novakova Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava , Slovakia.
  • Branislav Trebaticky Department of Urology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. https://orcid.org/0000-0001-5631-9633
  • Peter Bujdak Department of Urology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. https://orcid.org/0000-0001-6326-9478
  • Stefan Galbavy Institute of Forensic Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. https://orcid.org/0000-0001-9503-0971
  • Lubos Danisovic | lubos.danisovic@fmed.uniba.sk Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava , Slovakia. https://orcid.org/0000-0002-5074-9621

Abstract

Although the incidence varies with age and gender, urothelial bladder cancer is a relatively frequently occurring malignancy with variable clinical behavior that often has high recurrence rates. In this study, we analyzed the tumor tissues of 224 patients with pTa, pT1, and pT2 urinary bladder cancer. We performed a histomorphologic analysis and immunohistochemistry for p53, Ki-67, and E-cadherin, which were selected as markers of the malignant process. For pTa and pT1, univariate analyses of cancer-specific survival (CSS), progression-free survival (PFS), and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method, the log-rank test and Cox regression. Multivariate analysis was performed by a Cox regression analysis. Ki-67 (P<0.001) was significantly associated with CSS, but the highest association was shown for E-cadherin (P<0.001). For pT1 and pTa, the Kaplan-Meier analysis and the log-rank test revealed significantly worse PFS for patients with higher levels of Ki-67 (P<0.001) and lower levels of E-cadherin (P<0.001). Based on these obtained results, it can be clearly stated that Ki-67 and E-cadherin expression levels are associated with CSS, PFS and RFS. The clinical utility of these markers is valuable for pTa and pT1 urinary bladder cancer and should be further verified with prospective multi-center trials.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2020-03-26
Info
Issue
Section
Articles
Supporting Agencies
This research was funded by the grant VEGA no. 1/0207/16
Keywords:
urothelium, bladder, cancer, E-cadherin, Ki-67, p53
Statistics
  • Abstract views: 412

  • PDF: 227
  • HTML: 0
How to Cite
Ziaran, S., Harsanyi, S., Bevizova, K., Varchulova Novakova, Z., Trebaticky, B., Bujdak, P., Galbavy, S., & Danisovic, L. (2020). Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. European Journal of Histochemistry, 64(2). https://doi.org/10.4081/ejh.2020.3098